Publications
Featured Publication
Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia
N Engl J Med 2021; 384:717-726
View
Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial
Lancet 2023
View
Potential Impact of KarXT on Negative Symptoms in Acute Schizophrenia: An Analysis of Pooled Data From 3 Trials
CNS Summit; 2023 November 8-11.
View
Pooled Analysis of EPS-Like Symptoms in the EMERGENT Program of KarXT in Schizophrenia
Neuroscience Education Institute (NEI) Congress; 2023 November 9-12.
View
Safety and Tolerability of KarXT (Xanomeline-Trospium): Pooled Results From the Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials
Neuroscience Education Institute (NEI) Congress; 2023 November 9-12.
View
Efficacy of KarXT (Xanomeline-Trospium) in Schizophrenia: Pooled Results From the Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials
Neuroscience Education Institute (NEI) Congress; 2023 November 9-12.
View
Onset, Duration, and Severity of Adverse Events With KarXT (Xanomeline–Trospium) in the Randomised, Double-Blind, Placebo-Controlled Phase 3 EMERGENT-3 Trial
36th European College of Neuropsychopharmacology (ECNP) Congress; 2023 October 7-10.
View
Categorical Response Rates, Time Course of Response, and Symptom Domains of Response With KarXT (Xanomeline–Trospium) in the EMERGENT-3 Trial
36th European College of Neuropsychopharmacology (ECNP) Congress; 2023 October 7-10.
View